Drug Update · Dermatology

Adapalene–Benzoyl Peroxide Gel (Differin Epiduo) Added to FDA Rx‑to‑NonRx Switch List 5/22/2026

September 10, 2026

Regulatory action

Added to FDA Prescription to Nonprescription Switch List on 5/22/2026

Indication

Topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older

Dosing summary

Apply a thin layer once daily; pea-sized amount per facial area

Label effective date

2026-05-20

Clinical Perspective

Clinicians who treat dermatology patients and primary care clinicians managing acne should note that Differin Epiduo (adapalene 0.1%/benzoyl peroxide 2.5% gel) is listed on the FDA Prescription to Nonprescription Switch List with an entry dated 5/22/2026, and the approved labeling covers topical treatment of acne in adults and pediatric patients 12 years and older ^[3]^[1]^[4]. The labeling and DailyMed highlights support once-daily topical application of a thin layer to affected areas and list the most common local cutaneous adverse reactions observed in trials ^[1]^[2]^[4]. How this regulatory listing will affect availability at retail or over-the-counter distribution channels was not reported in the provided source excerpts.

Dr. Divya Agarwal, MBBS, MD (Dermatology, Venereology & Leprosy) · Dermatology

The FDA added Differin Epiduo (adapalene 0.1% and benzoyl peroxide 2.5% gel) to the Prescription to Nonprescription Switch List on 5/22/2026, identifying the product and date of the regulatory action ^[3]. Label information effective 2026-05-20 shows directions for topical treatment of acne in adults and children 12 years of age and older with once-daily application to affected areas ^[4]^[1]^[2].

Clinical Context

Adapalene and benzoyl peroxide fixed-dose gels combine a retinoid (adapalene) with an oxidizing antimicrobial/keratolytic agent (benzoyl peroxide) in an aqueous gel formulation ^[1]^[2]. The combination products described in the provided sources include adapalene 0.1%/benzoyl peroxide 2.5% and adapalene 0.3%/benzoyl peroxide 2.5% topical gels, with initial U.S. approvals listed for the formulations in prior years and prescribing information summarizing indications and dosing ^[1]^[2]. The FDA Prescription to Nonprescription Switch List entry names Differin Epiduo (adapalene 0.1%/benzoyl peroxide 2.5% gel) and lists an approval date of 5/22/2026 for that NDA entry ^[3]. Full prescribing and safety information is available in the product labeling and DailyMed highlights ^[1]^[2]^[4].

Key Findings

The FDA Prescription to Nonprescription Switch List includes NDA 220736 Differin Epiduo (adapalene 0.1% and benzoyl peroxide 2.5% gel) with an approval date of 5/22/2026 ^[3].
The product is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older according to the labeling and the FDA list entry ^[1]^[2]^[3].
The most-recent label effective date is 2026-05-20 and the FDA API entry lists an original approval date of 2026-05-22 for the approved labeling update that corresponds to this regulatory action; the label directs once-daily application to affected areas with a thin layer, and gives the example of a pea-sized amount per facial area ^[4]^[1]^[2].

Safety & Tolerability

Most commonly reported adverse events (≥1%) with adapalene and benzoyl peroxide gel, 0.1%/2.5% included dry skin, contact dermatitis, application site burning, application site irritation, and skin irritation ^[1].
In clinical trials of adapalene and benzoyl peroxide gel, 0.1%/2.5%, 14% of subjects had an adverse event reported versus 4% with vehicle; dry skin occurred in 7% versus 2% with vehicle, contact dermatitis in 3% versus <1% with vehicle, application site burning 2% versus <1% with vehicle, and application site irritation 1% versus <1% with vehicle ^[1].
Local tolerability assessments in trials showed treatment-emergent erythema, scaling, dryness, and stinging/burning that peaked at Week 1 and decreased thereafter; incidence figures for maximum severity during treatment included erythema (27% mild, 13% moderate, 1% severe), scaling (35% mild, 11% moderate, 1% severe), dryness (41% mild, 13% moderate, 1% severe), and stinging/burning (41% mild, 15% moderate, 3% severe) for the 0.1%/2.5% formulation in controlled trials ^[1].
For adapalene and benzoyl peroxide topical gel, 0.3%/2.5%, clinical trials reported adverse reactions occurring in ≥1% including skin irritation, eczema, atopic dermatitis, and skin burning sensation, and local tolerability also peaked at Week 1 and decreased thereafter ^[2].
Postmarketing adverse reactions reported for the 0.1%/2.5% gel include eyelid edema, sunburn, blister, pain of skin, pruritus, swelling face, conjunctivitis, skin discoloration, rash, eczema, throat tightness and allergic contact dermatitis ^[1]. Postmarketing reports for the 0.3%/2.5% gel include sunburn, blister, pruritus, hyperpigmentation and hypopigmentation ^[2].

Study Design

Regulatory action: The FDA Prescription to Nonprescription Switch List documents the inclusion of NDA 220736 Differin Epiduo (adapalene 0.1% and benzoyl peroxide 2.5% gel) with an approval date of 5/22/2026 ^[3]. Label metadata from FDA prescribing information shows a label effective date of 2026-05-20 and an FDA original approval date of 2026-05-22 for the current FDA entry ^[4]. Clinical trial exposure data in the prescribing information for adapalene and benzoyl peroxide gel, 0.1%/2.5% report that 1,401 subjects were exposed overall and that 1,036 subjects with acne vulgaris 12 years and older were treated once daily for 12 weeks to 12 months in clinical studies summarized in the labeling ^[1]. Clinicians should consult current prescribing information for full dosing guidance. Detailed trial phase, randomization schema, and primary efficacy endpoint results were not reported in the provided source excerpts.

FAQ

Q1 What is Differin Epiduo (adapalene and benzoyl peroxide) approved for?

Differin Epiduo (adapalene 0.1% and benzoyl peroxide 2.5% gel) is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older according to the product labeling and the FDA Prescription to Nonprescription Switch List entry dated 5/22/2026. The DailyMed highlights reiterate the topical acne indication in patients 9 years of age and older for the 0.1%/2.5% formulation but the current FDA list and label entries specify adults and children 12 years and older for the listed NDA.

Q2 How does adapalene plus benzoyl peroxide work?

Adapalene is a synthetic retinoid that binds to specific retinoic acid nuclear receptors and is described in the prescribing information as a modulator of cellular differentiation, keratinization and inflammatory processes. Benzoyl peroxide is characterized in the labeling as an oxidizing agent with bactericidal and keratolytic effects; benzoyl peroxide is rapidly metabolized in the skin to benzoic acid and eliminated in the urine.

Q3 What is the recommended dose and application method?

The labeling directs application of a thin layer of the gel once daily to affected areas of the face and/or trunk after washing; the label gives the example of using a pea-sized amount for each area of the face (forehead, chin, each cheek). The label also instructs to avoid the eyes, lips and mucous membranes and states that applying more than directed will not provide faster or better results but may worsen skin irritation. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects and tolerability considerations?

Clinical trial and labeling data for the adapalene and benzoyl peroxide combination gels list local cutaneous reactions including erythema, scaling, dryness, stinging/burning, dry skin, contact dermatitis, application site burning, application site irritation and skin irritation as the most commonly reported adverse events. Trial data summarized in the labeling indicate that local tolerability signs and symptoms peak at Week 1 and often decrease with continued use; postmarketing reports include eyelid edema, sunburn, blister, pruritus, hyperpigmentation and hypopigmentation among others.

Clinicians should consult current prescribing information for complete dosing guidance.

Adapalene–Benzoyl Peroxide Gel (Differin Epiduo) Added to FDA Rx‑to‑NonRx Switch List 5/22/2026

Direct Clinical Takeaway & Evidence Summary

Adapalene–Benzoyl Peroxide Gel (Differin Epiduo) Added to FDA Rx‑to‑NonRx Switch List 5/22/2026

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Cite & Reference This Monograph

Get weekly clinical updates for Dermatology in your inbox.

Related Clinical Updates

risankizumab pediatric approval: weight‑based 55 mg for <40 kg in ages 6+

FDA Adds Bemotrizinol to OTC Sunscreen Monograph

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

Verified HCP Portal